Salarius Pharmaceuticals, Inc. — FY 2019 Form 10-K
Entity and period: The supplied filing is for Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), not Decoy Therapeutics Inc. It covers the fiscal year ended December 31, 2019; the filing does not provide a clear standalone Q4 financial summary. The July 19, 2019 merger with Flex Pharma was accounted for as a reverse acquisition, with Private Salarius treated as the accounting acquirer. Historical comparisons therefore reflect Private Salarius, not Flex Pharma, before the merger.
Business context and development
Salarius is a clinical-stage biotechnology company with no approved products or product-sale revenue. Its lead candidate, oral LSD1 inhibitor seclidemstat (SP-2577), was being studied in active Phase 1/2 trials for relapsed or refractory Ewing sarcoma and advanced solid tumors. The Ewing sarcoma program had reached dose level 5 by year-end 2019. The FDA granted Fast Track designation for SP-2577 in Ewing sarcoma in December 2019; this does not assure approval or a faster review.
Financial results and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Grant revenue | $3.47 million | $1.95 million |
| Research and development expense | $4.02 million | $1.29 million |
| General and administrative expense | $7.71 million | $2.35 million |
| Net loss | $6.94 million | $1.67 million |
| Net loss per common share | $2.12 | $1.16 |
| Net cash used in operating activities | $11.58 million | Net cash provided: $4.18 million |
- All 2019 revenue was from the CPRIT research grant; Salarius had no product-sale revenue. Gross margin is not meaningful for this development-stage business.
- R&D expense rose $2.73 million, mainly due to clinical-trial and drug-manufacturing activities. G&A rose $5.36 million, largely due to merger and financing legal/professional costs, including a $1.35 million merger success fee, higher insurance, and payroll.
- A $1.31 million gain from the change in fair value of warrant liability partially offset operating losses. This was a non-cash, valuation-sensitive item.
- At year-end, cash and cash equivalents were $3.74 million, working capital was $1.38 million, total assets were $13.89 million, and total liabilities were $3.31 million. Current liabilities included a $502,332 note payable and $541,701 deferred grant revenue. The filing reports no material long-term borrowing.
- Cash used in operating activities was partly offset by $5.61 million of investing cash inflows, principally cash received in the reverse acquisition; financing provided $3.58 million. The year-end cash balance was down from combined cash, cash equivalents and restricted cash of $6.13 million at the start of the year.
Material changes and subsequent events
- Losses widened year over year, while grant revenue increased with reimbursable spending. Comparisons are affected by the reverse acquisition and merger-related expenses.
- On February 11, 2020, Salarius completed an offering generating approximately $11.0 million gross, before fees and expenses, through common-stock and convertible-preferred units with five-year warrants. The financing was dilutive and included potential additional shares from warrant exercise and preferred-stock conversion.
- Management stated that cash on hand was expected to fund anticipated operations for at least 12 months from the report’s filing date, taking the February 2020 financing into account. The company nevertheless expected to need substantial additional capital.
- Salarius had received $9.6 million cumulatively under its CPRIT award, with $9.1 million reportedly available subject to requirements. The award, originally due to expire in May 2019, had extensions through May 31, 2020; matching-fund and other grant conditions apply. The company reported that matching requirements had been met at year-end.
- The company reported that a prior material weakness in financial-reporting controls had been remediated and that management considered internal control over financial reporting effective at December 31, 2019. The auditor did not provide an opinion on internal control effectiveness.
Outlook, risks and unusual items
- No revenue, earnings, or clinical-outcome guidance was provided. Management expected continued significant operating losses and higher development costs; product revenue depends on successful trials, regulatory approval, and commercialization.
- Key risks include early-stage clinical uncertainty, safety and efficacy outcomes, patient enrollment, dependence on contract manufacturers and research organizations, competition, patent and licensing risks, and the need for additional financing. Fast Track, orphan and potential rare-pediatric-disease incentives do not assure approval or a priority review voucher.
- The CPRIT grant may require repayment in specified circumstances and could impose revenue-sharing obligations upon commercialization. Grant funding is conditional and matching funds are required.
- The filing discussed possible business disruption from COVID-19 and the Defense Production Act, while noting that the impact was still being assessed.
- The company disclosed a March 16, 2020 closing share price of $0.6995 and warned that a sustained bid below $1.00 could create Nasdaq listing-compliance risk. It also disclosed a Chief Business Officer’s planned departure effective April 30, 2020 and an interim Chief Scientific Officer arrangement.
- The independent auditor issued an unqualified opinion on the 2019 financial statements. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the post-offering share count, warrant overhang, preferred-stock conversion terms, and net proceeds after offering costs.
- Review current cash burn and runway against the stated 12-month expectation, including spending on both Phase 1/2 trials.
- Verify CPRIT draw availability, matching-fund compliance, grant-extension status, and any repayment or future revenue-sharing exposure.
- Track trial enrollment, dose escalation, safety findings, and any evidence of efficacy; the filing reports early-stage trials, not established clinical benefit.
- Reconcile year-over-year cash-flow comparisons with the reverse acquisition, acquired cash, HOTSHOT business disposal, and merger-related payments.
- Check Nasdaq listing status and the potential dilution and market impact of outstanding or newly issued warrants and shares.